Myriad Genetics Signs Marketing Plans With Pfizer For BRACAnalysis CDx Test
Executive Summary
Myriad Genetics, Inc. and Pfizer Inc. signed an agreement to promote Myriad's BRACAnalysis CDx test, currently under US FDA review, as a companion diagnostic for Pfizer's investigational breast cancer drug, talazoparib.
You may also be interested in...
Pacts In Medtech: Myriad/Pfizer Deal Headlines Oncology-Heavy List Of Deals In September And October
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in September and October 2018.
Liquid Biopsy In Oncology: An Increasingly Crowded Landscape
Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.
Mosie Baby First To Win FDA Clearance For At-Home DYI Artificial Insemination Kit
Austin-based start-up Mosie received FDA clearance for a home insemination kit to help people get pregnant. The kit retails for $129.99.